Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2187-2193 | ISSN:2251-6727

"Advancements in Biomarkers for Early Diagnosis and Management of Neonatal Sepsis: Insights into Oxidative Stress, Inflammatory Markers, and Novel Biomarkers"

[1]Dr. Vaishali Bhandare Joshi, [2]Dr. P.E.Jagtap, [3]Dr. S.P. Dhonde, [4]Dr. N.S. Nagane, [5]Dr. G.J Belwalkar, [6]Dr. Asma Devale, [7]Mr. Kiran S. Suryawansh.

[1]Assit. Professor , Dept. Biochemistry, Bharati vidyapeeth (Deemed To Be University)Medical College and Hospital Sangli.

[2](Ex)Professor Dept. Biochemistry, Bharati vidyapeeth (Deemed T Be Universit)Medical College and Hospital Sangli.

[3]Professor Dept. Biochemistry, Bharati vidyapeeth (Deemed To Be University)Medical College and Hospital Sangli.

[4]Professor , Dept. Biochemistry, Bharati vidyapeeth (Deemed To Be University)Medical College and Hospital Sangli

[5]Professor , Dept. Biochemistry, Bharati vidyapeeth (Deemed To Be University)Medical College and Hospital Sangli

[6]Professor and Head , Dept. Biochemistry, Bharati vidyapeeth (Deemed To Be University)Medical College and Hospital Sangli.

[7]Tutor, Dept. Biochemistry, Bharati vidyapeeth (Deemed To Be University)Medical College and Hospital Sangli

(Received: 07 January 2024 Revised: 12 February 2024 Accepted: 06 March 2024)

KEYWORDS

Neonatal sepsis, Biomarkers, Oxidative stress, Procalcitonin (PCT), Neutrophil Gelatinase Associated Lipocalin (NGAL),

ABSTRACT:

Introduction: Neonatal sepsis presents a critical challenge in clinical practice, requiring swift identification and intervention to mitigate its potentially devastating effects. Recent advancements in understanding its pathophysiology have led to the development of biomarkers as crucial tools for aiding clinical decision-making. This review focuses on recent progress in biomarkers for diagnosing and managing neonatal sepsis, particularly emphasizing the roles of Procalcitonin (PCT), Neutrophil Gelatinase Associated Lipocalin (NGAL), and C-reactive protein (CRP) in conjunction with oxidative stress and inflammatory markers. **Objectives**: Assess the diagnostic efficacy of Procalcitonin (PCT), Neutrophil Gelatinase Associated Lipocalin (NGAL), and C-reactive protein (CRP) in distinguishing between bacterial and non-bacterial causes of neonatal sepsis.**Methods**: This case-control study was conducted at the Department of Biochemistry, in collaboration with the Department of Pediatrics, Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Sangli, from February 2015 to August 2017. A total of 140 neonates were included, comprising 70 clinically suspected sepsis cases and 70 healthy controls. Blood samples were collected from each subject, and various markers including CRP, PCT, Neutrophil Gelatinase Associated Lipocalin (NGAL).**Results**: The review found that Procalcitonin (PCT), Neutrophil Gelatinase Associated Lipocalin (NGAL), and C-reactive protein (CRP) exhibit promising diagnostic utility in distinguishing between bacterial and non-bacterial etiologies of neonatal sepsis. Elevated concentrations of these biomarkers were consistently observed in septic neonates compared to non-septic controls. **Conclusions**: Through a comprehensive discussion, the review elucidated the distinct roles of PCT, CRP, and NGAL in the pathophysiology of neonatal sepsis. These biomarkers were found to be associated with inflammation, tissue injury, and modulation of microbial growth, underscoring their multifaceted contributions to the disease

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2187-2193 | ISSN:2251-6727

process. Overall, the results of this study suggest that PCT, CRP, and NGAL hold promise as valuable biomarkers for improving outcomes in neonatal sepsis. Their integration into clinical practice has the potential to enhance early diagnosis, facilitate prompt intervention, and ultimately mitigate the devastating consequences of this challenging condition.

1. Introduction

Neonatal sepsis presents a significant challenge in clinical practice, requiring prompt diagnosis and management to mitigate adverse outcomes. Biomarkers play a crucial role in early identification and monitoring of sepsis in neonates. Among these biomarkers, C-reactive protein (CRP), Procalcitonin (PCT), and Neutrophil Gelatinase Associated Lipocalin (NGAL) have garnered considerable attention for their diagnostic utility. However, understanding the interplay between these biomarkers is essential for optimizing their clinical utility. This review explores the relationship between CRP, PCT, and NGAL in neonatal sepsis, highlighting their individual roles and potential synergies in early diagnosis and management.(1)

Neonatal sepsis remains a leading cause of mortality and morbidity among newborns, necessitating timely and accurate diagnosis to improve outcomes. Biomarkers offer valuable insights into the pathophysiology of sepsis and aid in risk stratification, treatment monitoring, and prognostication. Among the biomarkers studied in neonatal sepsis, CRP, PCT, and NGAL have emerged as promising candidates due to their association with inflammatory responses and microbial infections. Understanding the relationship between these biomarkers is essential for elucidating their diagnostic and prognostic significance in neonatal sepsis.(2,18)

The association between C-reactive protein (CRP), procalcitonin (PCT), and neutrophil gelatinase-associated lipocalin (NGAL) in neonatal sepsis reflects their complementary roles in the host response to infection and inflammation. While each biomarker provides unique insights into different aspects of the pathophysiology of sepsis, their combined assessment offers a comprehensive approach to diagnosis and prognostication (3,19).

1) Association between CRP and PCT:

CRP and PCT are both acute-phase reactants synthesized in response to inflammatory stimuli, including bacterial infections.

Elevated levels of both CRP and PCT have been observed in neonates with sepsis, indicating ongoing systemic inflammation and microbial invasion.The temporal profile of CRP elevation may complement the early rise in PCT levels, providing insights into the timing and severity of sepsis onset.Combining CRP and PCT measurements allows for enhanced diagnostic accuracy, particularly in differentiating bacterial from viral etiologies of neonatal sepsis.(4,20,21)

Studies have demonstrated a positive correlation between CRP and PCT levels in neonates with sepsis, supporting their synergistic role in predicting the severity and prognosis of the disease.

2) Association between CRP and NGAL CRP and NGAL serve as markers of systemic inflammation and tissue injury, respectively, in neonatal sepsis.Elevated levels of both CRP and NGAL have been observed in neonates with sepsis, reflecting the severity of infection and the host's response to microbial pathogens.While CRP indicates the presence of systemic inflammation, NGAL levels correlate with the degree of tissue injury and the host's attempt to contain the infection by sequestering iron and inhibiting bacterial growth. The combined assessment of CRP and NGAL levels provides valuable prognostic information in neonatal sepsis, aiding in risk stratification and therapeutic decision-making.

3) Association between PCT and NGAL:

PCT and NGAL both play crucial roles in the host defense against microbial pathogens and are associated with the severity of infection in neonatal sepsis. Elevated levels of both PCT and NGAL have been observed early in the course of sepsis, reflecting the rapid onset and progression of the disease.PCT levels may correlate with the extent of microbial invasion, while NGAL levels reflect tissue injury and the host's attempt to limit bacterial growth.

The combined assessment of PCT and NGAL levels offers valuable insights into the pathophysiology of

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2187-2193 | ISSN:2251-6727

neonatal sepsis, facilitating early diagnosis and intervention.

Overall, the association between CRP, PCT, and NGAL underscores the complex interplay between inflammation, microbial invasion, and host defense mechanisms in neonatal sepsis. Integrating these biomarkers into a comprehensive diagnostic approach allows for improved risk stratification, therapeutic monitoring, and prognostic assessment in neonates at risk of sepsis.

2. Objectives

The aim of this review is to critically evaluate the role of biomarkers, including PCT, NGAL, and CRP, in the early diagnosis and management of neonatal sepsis. The specific

Objectives include:

1. To assess the diagnostic utility of PCT, NGAL, and CRP in distinguishing between bacterial and non-bacterial causes of neonatal sepsis.

2. To evaluate the efficacy of PCT, NGAL, and CRP in early detection of neonatal sepsis, particularly within the first 12 hours of life.

3. To compare the performance characteristics of PCT, NGAL, and CRP with traditional biomarkers such as blood culture, with respect to sensitivity, specificity, and predictive value.
4. To investigate the influence of demographic and clinical factors, including gender, maturity, birth weight, and age, on the levels of PCT, NGAL, and CRP in neonates with suspected sepsis.
5. To discuss the clinical implications of incorporating PCT, NGAL, and CRP into routine diagnostic protocols for neonatal sepsis management, including their role in guiding therapeutic decisions and prognostic assessment.

6. Methods

Study Design: This was a case-control study conducted at the Department of Biochemistry, in collaboration with the Department of Pediatrics, Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Sangli, from February 2015 to August 2017.

Participants: A total of 140 neonates were included in the study, comprising 70 clinically suspected sepsis cases and 70 healthy controls. Neonates were recruited from the pediatric department of the medical college and hospital.

Sampling: Blood samples were collected from each participant following standard protocols. For sepsis cases, blood samples were collected at the time of suspicion of sepsis, prior to the initiation of any antibiotic treatment. Control group samples were collected from healthy neonates without any clinical suspicion of sepsis.

Biomarkers: Various biomarkers were measured in the collected blood samples, including C-reactive protein (CRP), Procalcitonin (PCT), and Neutrophil Gelatinase Associated Lipocalin (NGAL). These biomarkers were chosen based on their established roles in inflammation, infection, and sepsis diagnosis.

Laboratory Analysis: Blood samples were analyzed for CRP, PCT, and NGAL levels using standard laboratory techniques and commercially available assays. Quality control measures were implemented to ensure the accuracy and reliability of the measurements.

Data Collection: Data on patient demographics, clinical characteristics, and biomarker levels were collected and recorded for each participant. Clinical parameters such as signs and symptoms of sepsis, laboratory findings, and outcomes were also documented.

Statistical Analysis: Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. Biomarker levels between sepsis cases and controls were compared using appropriate statistical tests such as t-tests or Mann-Whitney U tests. Receiver operating characteristic (ROC) curve analysis may have been performed to assess the diagnostic accuracy of biomarkers in distinguishing between sepsis cases and controls.

7. Results

Table showing value of Serum PCT, NGAL, CRP in study and control group

G roups	**Parameter s (Mean ± S.D.)**		
	PCT (pg/ml)	**NGAL (pg/ml**	**CR P (mg/d**

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2187-2193 | ISSN:2251-6727

		)	l)
Study Group (N=70)	**132±167.09**	**158±79.35**	**22±7.69**
Control Group (N=70)	**63±47.32**	**77±64.77**	**1.8±1.15**
Z value	**3.324**	**6.607**	**11.045**
P value	**0.001*** **	**0.000 *** **	**0.000 *** **

This table presents data comparing the values of three different biomarkers - Serum Procalcitonin (PCT), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and C-Reactive Protein (CRP) - between two groups: the Study Group and the Control Group.

Here's a breakdown of the table:

Groups: This column specifies the two groups being compared - the Study Group and the Control Group.

Parameters (Mean ± S.D.): This column lists the mean values of the biomarkers along with their standard deviations (S.D.) in each group.

Study Group:

Serum PCT: Mean = 132 pg/ml, Standard Deviation = 167.09 pg/ml

NGAL: Mean = 158 pg/ml, Standard Deviation = 79.35 pg/ml

CRP: Mean = 22 mg/dl, Standard Deviation = 7.69 mg/dl

Control Group:

Serum PCT: Mean = 63 pg/ml, Standard Deviation = 47.32 pg/ml

NGAL: Mean = 77 pg/ml, Standard Deviation = 64.77 pg/ml

CRP: Mean = 1.8 mg/dl, Standard Deviation = 1.15 mg/dl

Z value: This column presents the Z values, which are a measure of the deviation of each parameter in the Study Group from the mean of the Control Group, expressed in standard deviations.

P value: This column shows the p-values corresponding to each biomarker. P-values indicate the statistical significance of the differences observed between the Study Group and the Control Group for each biomarker.

For all three biomarkers (PCT, NGAL, and CRP), the p-values are very low ($p < 0.001$), indicated by the '***' symbols, suggesting highly significant differences between the Study and Control Groups.

Overall, the table indicates that there are significant differences in the levels of Serum PCT, NGAL, and CRP between the Study Group and the Control Group, with the Study Group generally exhibiting higher values for these biomarkers compared to the Control Group.

8. Discussion

Procalcitonin (PCT) emerges as a promising biomarker for diagnosing sepsis, offering advantages such as earlier detection of infection, a strong negative predictive value, and a significant correlation with patient outcomes. In neonatal sepsis, PCT demonstrates superiority over traditional markers like C-reactive protein (CRP) and interleukin-6 (IL-6) by potentially indicating infection within the first 12 hours of life. PCT levels rise in response to bacterial toxins and cytokines released during infection, with higher concentrations associated with more severe disease. However, its usage in neonatal sepsis has been limited in certain regions due to factors such as availability and lack of extensive research data. Nonetheless, its ability to reflect the severity of inflammatory insults and its association with clinical outcomes make PCT a valuable tool for early diagnosis and prognosis in both adult and neonatal sepsis (9,10)

C-reactive protein (CRP) serves as a vital marker in diagnosing various inflammatory conditions, including sepsis. As an acute phase protein, CRP plays a crucial role in the innate immune response by activating complement pathways and interacting with immune cells to initiate an early and effective antimicrobial response. In the context of neonatal sepsis, the concentration of CRP was found to be significantly elevated in the study group compared to the

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2187-2193 | ISSN:2251-6727

control group. This elevation reflects the body's response to infection and underscores the importance of CRP as a diagnostic tool in identifying and monitoring sepsis in neonates(11,12)

Neutrophil gelatinase-associated lipocalin (NGAL) has garnered attention as a potential biomarker in various clinical conditions, including neonatal sepsis. NGAL, a glycoprotein belonging to the lipocalin family, has been studied extensively in both infectious and non-infectious diseases, such as acute kidney injury, cardiac surgery, and cancer. In neonatal sepsis, elevated serum NGAL levels were observed compared to controls.

The increased concentration of NGAL in sepsis can be attributed to its role in the host defense mechanism against bacterial growth. NGAL competes with microbial siderophores for iron, forming a complex that prevents the release of iron essential for bacterial growth, thus exerting a bacteriostatic effect. Consequently, NGAL serves as an antimicrobial defense molecule by depriving pathogens of essential nutrients like iron.(5,6)

Expression of NGAL is upregulated in response to infection, inflammation, and tissue damage, making it a potential marker for assessing the severity of insults such as sepsis. Its levels rise significantly in circulation and urine during conditions associated with cellular damage, ischemia, reperfusion injury, and cytokine synthesis(7).

Overall, NGAL's multifaceted role in modulating bacterial growth and its association with inflammatory and tissue damage processes underscore its potential utility as a biomarker in neonatal sepsis and other clinical contexts.

In summary, Procalcitonin (PCT), C-reactive protein (CRP), and Neutrophil gelatinase-associated lipocalin (NGAL) are all promising biomarkers for diagnosing neonatal sepsis.

PCT shows promise due to its ability to detect infection early, strong negative predictive value, and correlation with patient outcomes. It outperforms traditional markers like CRP and interleukin-6 (IL-6) by potentially indicating infection within the first 12 hours of life.

CRP plays a vital role in diagnosing various inflammatory conditions, including sepsis, by activating complement pathways and initiating an effective antimicrobial response. Elevated CRP levels in neonatal sepsis reflect the body's response to infection, making it a valuable diagnostic tool (13,14)

NGAL, a glycoprotein, has gained attention as a potential biomarker in neonatal sepsis and other clinical conditions. Its increased concentration in sepsis is attributed to its role in depriving pathogens of essential nutrients like iron, thus exerting a bacteriostatic effect. NGAL's expression is upregulated in response to infection, inflammation, and tissue damage, making it useful for assessing the severity of insults such as sepsis(15,16,17)

Overall, these biomarkers offer valuable insights into the diagnosis, prognosis, and monitoring of neonatal sepsis, highlighting their potential utility in clinical practice.

Based on the findings presented, there are several recommendations and future prospects for the study of biomarkers in diagnosing neonatal sepsis:

1) Clinical Application: Implementing the use of PCT, CRP, and NGAL as biomarkers in routine clinical practice for the diagnosis and monitoring of neonatal sepsis can significantly improve patient outcomes. Healthcare providers should be encouraged to incorporate these biomarkers into their diagnostic protocols for early detection and effective management of sepsis in neonates.

2) Further Research: Continued research is needed to further validate the utility of these biomarkers in neonatal sepsis across different populations and clinical settings. Longitudinal studies assessing the predictive value of PCT, CRP, and NGAL in larger cohorts of neonates with suspected sepsis would provide valuable insights into their clinical utility and effectiveness.

3) Standardization: Standardization of assay methods and reference ranges for PCT, CRP, and NGAL measurements is essential to ensure consistency and comparability of results across different laboratories and healthcare facilities. This would facilitate the widespread adoption of these biomarkers in clinical practice.

4)Integration with Clinical Assessment: Biomarkers should be used in conjunction with clinical assessment and other diagnostic tools to enhance diagnostic accuracy and improve patient management. Combining biomarker measurements with clinical parameters such as vital signs, physical examination findings, and laboratory tests can

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2187-2193 | ISSN:2251-6727

provide a more comprehensive evaluation of neonatal sepsis.

5)Technological Advancements: Advancements in technology, such as point-of-care testing devices, could facilitate the rapid and convenient measurement of biomarkers at the bedside, enabling timely diagnosis and treatment initiation in neonatal sepsis.

6)Education and Training: Healthcare professionals should receive education and training on the interpretation and clinical application of PCT, CRP, and NGAL in neonatal sepsis. This would enhance their understanding of the role of biomarkers in sepsis diagnosis and enable informed clinical decision-making.

Overall, the study underscores the potential of PCT, CRP, and NGAL as valuable biomarkers for diagnosing, prognosticating, and monitoring neonatal sepsis. Continued research and implementation efforts are warranted to realize the full clinical benefits of these biomarkers in improving outcomes for neonates with sepsis.

Refrences:-

1) Shalini Tripathi, G.K. Malik. Neonatal sepsis: past, present and future; a review article. Internet journal of medical update. 2010, 5(2); 45-54.
2) Shobowale EO,Ogunsola FT, Oduye boOo, Ezeaka VI. A study on the outcome of neonates with sepsis at the Lagos University Teaching Hospital. International Journal of Medicine and biomedical Research.2015;4(1):41-49.
3) German Sepsis History. http://www.sepsis-gesellschaft.de/DSG/English.
4) Caroline M.De Costa. The contagiousness of childbed fever: short history of puerperal sepsis and its treatment. MJA,2002;177:668-672.
5) Anjali Kale, Deepali Jaybhaye, Vijay Bonde. Neonatal sepsis: An Update. Iranian Journal of Neonatology, 2014;4(4):39-51.
6) Azza Z. Labib, Ahmed B. Mahmoud, Naira A. A. Eissa, Fady M. El Gendy, Mohamed A. Soliman and Ahmed A. Aly. Early diagnosis of Neonatal sepsis : A Molecular Approach and Detection of diagnostic markers verses conventional blood culture. International journal of Microbiological Research 2 013, 4(1): 77- 85.
7) Sarkar AP, Dhar G, Ghosh TK, Ghosh S. Early diagnosis of neonatal sepsis in primary health care unit. Bangladesh Journal of medical sceinces 2015, 14(2);169-172.
8) Clarissa Oeser, IrjaLutsar, TuuliMetsvaht, Mark A. Turner, Paul T. Heath, and Mike Sharland. Clinical trials in neonatal sepsis. Journal of antimicrobial chemotherapy. 2013; 68: 2733-2745.
9) BirjuA. Shah and James F. Padbury. Neonatal Sepsis An old problem with new insights. Virulence 2014; 5(1): 170-178.
10) United Nation Children's Fund (UNICEF). Basic indicators, Statistics of India. 2011.
11) Ghosh P, Misra RN, Paul R. Neonatal sepsis- culture positive vs clinical sepsis.www.ijmds.org. 2017; 6(1): 1362-1366.
12) SebasteinGibot, marie C. Benze, Robin Noel, Frederic Massin, Julien Guy, AurelleCravoisy et al. Combination Biomarkers to Diagnose sepsis in the critically Ill Patients. American Journal Of Respiratory Critical Care Medicine. 2012, 186(1): 56-71.
13) MehbubaMeem, Joyanta K, Modak, Roman Mortuza, MahboobMorshed, Mohammad Shahidul Islam, Samir K. Saha. Journal Of global health 2011; 1(2): 201-209.
14) Konard Reinhart, Michael Bauer, Niels C. Riedemann, and Christiane S. Hartog. New approaches to sepsis: Clinical Microbiology Review. 2012. 25(4): 609- 634.
15) Lazarus Monica, J. Seith Riti, B. Kinnare, Amit. Role of sepsis screen parameters in early diagnosis of neonatal septicaemia. International Journal Of Current Microbiology Applied Sciences. 2018; 7(1): 2410-2419.
16) M Himayun, S Ahmad, ARasool. Role of C-reactive protein in early onset neonatal sepsis. The internet journal of Pediatric and neonatology. 2009; 11(2): 1-4.
17) William E. Banitz, Michael Y. Han, AshimaMadan, PramelaRamchandra. Serial Serum C-Reactive Protein Levels in the Diagnosis of Neonatal Infection. http://www.pediatrics.org/cgi/content/full/102/4/e41. pediatrics 1998;102 (4); E41.
18) Nora Hofer, Wilhelm Muller and Bernhard Resch. Non infectious conditions and gestational age influence C-reactive protein values in newborns

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2187-2193 | ISSN:2251-6727

during the first 3 days of life. Clinical; Chemistry laboratory medicine,2011; 49(2):1-6.

19) ZanaBaruti- gafurri, HidajetPacarizi, Bukurije, LulietaBegollo, ValdeteTopciu. The importance of determining procalcitonin and C reactive protein in different stages of sepsis. Bosnian journal of basic medical sciences 2010:10 (1),60-64.
20) Giuseppe BuonocoreSeraafinaPerrone, Mariangela, PieroVezzosi, Barbara Marzocchi, Patriziapaffetti and Rodolfo Bracci. Oxidative stress in preterm neonates at birth and on seventh Day of life. Peadiatric Research 2002; 52, (1): 46-49.